CFTR and cystic fibrosis: While traditional functional imaging of intestinal organoids (FIS) is frequently employed to evaluate the specific effects of CFTR modulators on rare mutations (57, 58), research indicates that lung organoids offer superior phenotypic advantages in replicating CF pathological characteristics, including thickened mucus layers and electrolyte transport deficiencies (20, 59, 60).